A LARGE AGGRESSIVE PHOSPHATURIC MESENCHYMAL TUMOR OF THE HUMERUS
SURGICAL MANAGEMENT AND BUROSUMAB THERAPY FOR TUMOR-INDUCED OSTEOMALACIA
Keywords:
tumor-induced osteomalacia, phosphaturic mesenchymal tumor, burosumabAbstract
CASE
Tumor-induced osteomalacia (TIO) is a rare condition caused by phosphaturic mesenchymal tumors (PMTs) that overproduce FGF23, resulting in renal phosphate wasting. We present a case of a 74-year-old female with a right humeral fracture. MRI revealed a large (6.4x7.2x8.2 cm) enhancing lesion in the proximal right humerus, confirmed as a PMT by core biopsy. Laboratory findings showed persistent hypophosphatemia and FGF23 levels >30,000 pg/mL. The PMT was excised, and impaction bone allograft fixation was performed. Pathology results indicated a non-malignant tumor but with features warranting concern. The PET scan showed no metastatic disease, and residual tumor was suspected as the cause of persistent hypophosphatemia. Postoperatively, burosumab, an antibody targeting FGF23, was initiated to restore phosphorus levels and alleviate bone pain. This case underscores the complexity of managing TIO with a large PMT, necessitating a multidisciplinary approach involving various specialties. Burosumab demonstrates promise as an effective treatment option when surgical intervention alone may be insufficient.
Downloads
References
*
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Tasma Harindhanavudh, Andrea Espejo-Freire, Paari Murugan, Edward Cheng
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.